Can Fite Biopharma

CANF · TEL

$1.78−$0.05 (−2.73%)TodayMarket closed · Oct 23, 8:00 PM ET

Prev close $1.83

CANF analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $0.0504 (−97.2% downside)

Low: $0.0499
Now: $1.78
High: $0.0519

Upgrades and downgrades

The latest rating actions, newest first

CANF analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Jul 2, 2026	Maintains	Buy	$5.00 → $8.00	43%
D. Boral Capital	May 13, 2026	Upgrade	Hold → Buy	$7.00	28%
HC Wainwright & Co.	May 12, 2026	Maintains	Buy	$2.50 → $5.00	43%
D. Boral Capital	Dec 24, 2025	Downgrade	Buy → Hold	—	28%
D. Boral Capital	Dec 17, 2025	Maintains	Buy	$11.00 → $4.00	28%
D. Boral Capital	Nov 18, 2025	Maintains	Buy	$11.00	28%
HC Wainwright & Co.	Nov 4, 2025	Initiates	Buy	$2.50	43%

The case for and against

Updated Oct 22, 2026

Bull case

Can Fite Biopharma is supported by encouraging Phase 2a namodenoson data in advanced PDAC, where 20 patients showed a clean safety profile, more than 30% achieved stable disease, and the 3L subgroup posted median overall survival above 5 months with durability beyond seven months. The move into a planned Phase 2b combination study with chemotherapy and immunotherapy strengthens the commercial and strategic case, especially because the company has already secured multiple confidentiality agreements with potential partners and now includes PDAC cash flows in valuation. Beyond oncology, the piclidenoson pet osteoarthritis program adds additional upside through a $325M licensing deal, 118 enrolled dogs, and possible milestone payments that could provide non-dilutive capital.

Bear case

Can Fite Biopharma is a highly speculative clinical-stage company whose value depends on a narrow pipeline of unproven assets, leaving it exposed to commercial, regulatory, clinical, manufacturing, liability, partnership, and intellectual property risks. The financial profile remains weak, with FY2025 revenues of only $405K and a net loss of $5.97 per diluted share, while the 2026 outlook calls for no revenues and a further $1.39 per share loss, underscoring continued dependence on financing rather than operating cash flow. Although cash and cash equivalents were approximately $8.5M at year-end and about $4M is expected from warrant exercise, these funds mainly support near-term operations and do not eliminate dilution, competition, or development failure risk.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.